A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.
about
The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology AdvancementsEmerging PSA-based tests to improve screeningProstate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging rolesProstate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal BiomarkersHow Precisely Can Prostate Cancer Be Managed?A new method to assay protease based on amyloid misfolding: application to prostate cancer diagnosis using a panel of proteases biomarkersAgainst quantiles: categorization of continuous variables in epidemiologic research, and its discontents.Prostate-specific antigen screening in prostate cancer: perspectives on the evidencePrediction models in cancer care.Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.Identification of plasma protein profiles associated with risk groups of prostate cancer patientsPredicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.Screening for prostate cancer: early detection or overdetection?Personalized prostate cancer care: from screening to treatment.Biomarkers in prostate cancer surveillance and screening: past, present, and future.Recent progress and perspectives on prostate cancer biomarkers.Risk-based prostate cancer screening.PCA3 in the detection and management of early prostate cancer.The Kallikrein Panel for prostate cancer screening: its economic impact.The development of nomograms for stratification of men at risk of prostate cancer prior to prostate biopsy.Commercialized biomarkers: new horizons in prostate cancer diagnostics.Prostate-specific antigen-based prostate cancer screening: Past and future.Screening for Prostate Cancer-Beyond Total PSA, Utilization of Novel Biomarkers.A multiparametric approach to improve upon existing prostate cancer screening and biopsy recommendations.Clinical Utility of Biomarkers in Localized Prostate Cancer.Risk stratification of prostate cancer 2016.The 4Kscore blood test accurately identifies men with aggressive prostate cancer prior to prostate biopsy with or without DRE information.Biomarkers for Prostate Biopsy and Risk Stratification of Newly Diagnosed Prostate Cancer Patients.
P2860
Q26750672-3ED86050-13A1-458A-8B31-B0A6BCDBCC8AQ26828563-D92D153E-E953-4875-89B6-FF0ECB8BD829Q26865810-30B6B0E6-CD47-4985-8527-503EE7454DF7Q28075610-1949FB24-B5B9-42E3-932C-ED4F407929E1Q28078942-06DB67E4-3999-4CA0-AA00-AC86AFDBB763Q30437769-DE2E3E5B-83C5-4E15-B84F-1244F7777DADQ34178209-C9569E0B-2820-451E-BC88-9B70B16F8959Q34354430-833AA7E7-D4D8-4381-96B9-48459980AD8DQ35292878-D989D06A-E169-43A1-B763-02F5D538A452Q35718345-B711FBAE-4764-4271-8792-9EA7DD500A91Q35854594-05529913-7C48-4F5D-A717-64C71CAE23ADQ35940183-A707F193-FD1A-46C7-8B2D-B3C23438A677Q36009824-908796DB-DB9C-40AE-B0AF-949CC3CBA633Q36152421-F6D37182-95BF-4E65-B32E-DBDDAC418923Q37113160-943A7B5C-0DAF-44F5-9DDD-ECA9FFAC5EE9Q37300931-D727FF57-9817-466D-9E67-C319A837E04FQ37736079-53D84B03-F281-426A-912F-52E958D7F6D4Q37963657-D9C8D7C5-595B-4B9C-A3CC-70191EDEF9AEQ38090552-7846F810-6AEA-44E8-8A5E-F758E4C75E5CQ38156099-39D2A44D-6B58-4A5A-BC53-48FDB1F14914Q38165242-D562C4EB-EA60-481E-B531-052602334350Q38364797-BF80E712-1D63-4B0D-9D5C-EC088EC4E75EQ38408501-865EB4A1-C576-447D-9074-EBCDE78AF117Q38546301-EA91295D-214A-4FAA-A4AC-5725875E51D9Q38725930-465663F7-F2EA-4AF6-A4DC-F620C0F7D8F9Q38792354-70C9B853-BAB1-43C3-B953-86A39D2ADA06Q38929868-A63D744C-D775-4FA6-85F0-A7FBA608F353Q40469023-6EB5B7BD-B2E1-4A76-920E-758CD3F08721Q47718669-17D5BA3C-EE15-4595-88DC-384A8DC20C8C
P2860
A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A panel of kallikrein marker p ...... or 15 years without screening.
@ast
A panel of kallikrein marker p ...... or 15 years without screening.
@en
A panel of kallikrein marker p ...... or 15 years without screening.
@nl
type
label
A panel of kallikrein marker p ...... or 15 years without screening.
@ast
A panel of kallikrein marker p ...... or 15 years without screening.
@en
A panel of kallikrein marker p ...... or 15 years without screening.
@nl
prefLabel
A panel of kallikrein marker p ...... or 15 years without screening.
@ast
A panel of kallikrein marker p ...... or 15 years without screening.
@en
A panel of kallikrein marker p ...... or 15 years without screening.
@nl
P2093
P2860
P1476
A panel of kallikrein marker p ...... or 15 years without screening.
@en
P2093
Amit Gupta
Anders Bjartell
Anders Dahlin
Caroline J Savage
David Ulmert
Jonas Manjer
Kim Pettersson
Peter T Scardino
P2860
P304
P356
10.1158/1055-9965.EPI-10-1003
P577
2010-12-08T00:00:00Z